A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome.

Trial Profile

A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs AVE 0657 (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 29 Nov 2011 Status changed from recruiting to discontinued, according to ClinicalTrials.gov.
    • 09 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top